Top BUY-Rated Upgrades from ValuEngine

For today’s bulletin, we take a look at our latest BUY upgrades. We also provide a link to download a FREE STOCK REPORT on Eli LIlly $LLY, one of our top upgrades for the day.

VALUATION WATCH: Overvalued stocks now make up 48.92% of our stocks assigned a valuation and 19.72% of those equities are calculated to be overvalued by 20% or more. Twelve sectors are calculated to be overvalued.

For today’s edition of our upgrade list, we used our website’s advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. There were no STRONG BUY upgrades today. All of the stocks below are rated BUY. ALso, we did not have five upgrades with full data, so Anixa Biosceince was provided to fill out the list.

Ticker Company Name Market Price Valuation Last 12-M Return 1-M Forecast Return 1-Yr Forecast Return P/E Ratio Sector Name
ANIX ANIXA BIOSCIENC 5.16 N/A 88.32% 0.70% 8.39% N/A Business Services
DHT DHT HOLDINGS 5.02 3.71% 24.88% 0.69% 8.31% N/A Transportation
LLY LILLY ELI & CO 115.02 10.39% 31.23% 0.54% 6.43% 21.54 Medical
MEOH METHANEX CORP 81.86 20.83% 60.51% 0.52% 6.25% 10.93 Basic Materials
NRG NRG ENERGY INC 37.2 25.89% 45.48% 0.50% 6.02% 9.61 Utilities

Want to learn more about ValuEngine? Our methods? Our history?
Check out our video presentation HERE

Today, we take a look at Eli Lilly and Company (LLY). Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

ValuEngine updated its recommendation from HOLD to BUY for LILLY ELI & CO on 2018-10-05. Based on the information we have gathered and our resulting research, we feel that LILLY ELI & CO has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Company Size and Sharpe Ratio.

You can download a free copy of detailed report on Eli Lilly and Company (LLY) from the link below.

ValuEngine Forecast
1-Month 115.64 0.54%
3-Month 115.67 0.57%
6-Month 118.32 2.87%
1-Year 122.41 6.43%
2-Year 121.70 5.81%
3-Year 124.47 8.21%
Valuation & Rankings
Valuation 10.39% overvalued Valuation Rank(?) 33
1-M Forecast Return 0.54% 1-M Forecast Return Rank 86
12-M Return 31.23% Momentum Rank(?) 86
Sharpe Ratio 0.94 Sharpe Ratio Rank(?) 91
5-Y Avg Annual Return 15.14% 5-Y Avg Annual Rtn Rank 85
Volatility 16.17% Volatility Rank(?) 75
Expected EPS Growth 16.10% EPS Growth Rank(?) 49
Market Cap (billions) 128.07 Size Rank 100
Trailing P/E Ratio 21.54 Trailing P/E Rank(?) 55
Forward P/E Ratio 18.55 Forward P/E Ratio Rank 34
PEG Ratio 1.34 PEG Ratio Rank 31
Price/Sales 5.36 Price/Sales Rank(?) 20
Market/Book 36.43 Market/Book Rank(?) 5
Beta 0.28 Beta Rank 68
Alpha 0.19 Alpha Rank 85


DOWNLOAD A FREE SAMPLE OF OUR ELI LILLY (LLY) REPORT BY CLICKING HERE is an Independent Research Provider (IRP), producing buy/hold/sell recommendations, target price, and valuations on over 5,000 US and Canadian equities every trading day.
Contact ValuEngine at (321) 325-0519 or  
Visit for more information


ValuEngine Capital Management LLC is a Registered Investment Advisory (RIA) firm that trades client accounts using ValuEngine’s award-winning stock research.
Contact ValuEngine Capital at
Visit for more information


Steve Hach
Senior Editor